You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星系股價續漲逾6%-12% 郭廣昌指集團合作研發新冠疫苗有效性逾九成將提速國內落地
阿思達克 11-10 10:07
全球新冠肺炎確診病例突破5,000萬宗大關及累計死亡人數超過125萬人之際, 美國藥廠輝瑞(PFE.US)宣布與德國藥廠BioNTech(BNTX.US)聯手研發的疫苗取得重大進展,在第三階段測試中期結果顯示參與者在第二次注射疫苗後七天成功率超過九成,意味市民有望接種疫苗28天後便可防疫,形容是一項重大里程碑,消息刺激輝瑞及BioNTech昨晚股價分別急漲7.7%及近14%。

本港相關股復星醫藥(02196.HK)今早急漲高見39.5元,暫受制8月初所創52周高位41.6元,現造36.8元,續漲12.5%,成交急增至1,783萬股,涉資6.65億元。復星國際(00656.HK)高見10.82元,創四個月高,現造10.72元,續升6.3%,成交增至1,320萬股,涉資1.4億元。

內媒引述復星國際董事長郭廣昌於微博指,復星新冠疫苗在全球研發合作夥伴BioNTech與輝瑞聯手研發的mRNA疫苗有效性超90%,遠超此前預期,是全球合作的勝利,標誌著在這場面對新冠病毒的戰爭中已經看到了勝利的曙光。在復星新冠疫苗全球研發取得突破性進展之際,郭廣昌強調,復星將繼續與政府監管、審批部門密切溝通協同,希望根據全球研發的進展和數據分析的結果,在符合中國法規的前提下,推動復星新冠疫苗盡早在中國上市使用。據了解,復星旗下復星醫藥今年3月獲BioNTech授權,在中國大陸及港澳台地區獨家開發、註冊、商業化基於其專有mRNA技術平台研發的、針對新型冠狀病毒的復星新冠疫苗(暫定名「復必泰」),並於7月在國內啟動臨床試驗。目前,復星正與監管部門溝通,力爭盡快在國內啟動BNT162b2的橋接臨床試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account